In the last 25 years, the China A-share market capitalization surged over 10 times to RMB 85.96 trillion, shareholder returns grew more than 100 folds to RMB 1.94 trillion. The share of foreign ...
CORXEL, formerly Ji Xing, in 2020, acquired the rights to develop and commercialize aficamten in Greater China from Cytokinetics. Sanofi will now acquire CORXEL's rights relating to aficamten in ...
Sanofi will now acquire CORXEL’s rights relating to aficamten in Greater China for an undisclosed amount. Cytokinetics remains eligible to receive up to $150 million in development and ...
Morning Star Rating N.A. The primary investment objective of the Scheme is to provide long term capital appreciation by investing in JPMorgan Funds - Greater China Fund, an equity fund which ...
What is the category of Axis Greater China Equity Fund of Fund Direct Growth ? The category of Axis Greater China Equity Fund of Fund Direct Growth is Equity - Global - Other What is the current ...
Results that may be inaccessible to you are currently showing.